Faculty Profile, National Health Research Institutes, Taiwan

Faculty Profiles


Chung-Huang Hubert Chan, M.D., Ph.D.

Assistant Investigator & Attending Physician
National Institute of Cancer Research
hubertchan@nhri.org.tw

EDUCATION

Ph.D., Program of Pathobiology, Department of Laboratory Medicine and Pathology, University of Minnesota, USA, 1997
M.D., School of Medicine, Chung Shan Medical University, Taiwan, 1989

PROFESSIONAL EXPERIENCES

- Assistant Investigator & Attending Physician, National Institute of Cancer Research, National Health Research Institutes, Taiwan (2006-Present)
- Clinical Fellow (Medical Oncology), Division of Cancer Research, National Health Research Institutes, Taiwan (2003-2006)
- Resident (Internal Medicine), Department of Internal Medicine, Veterans General Hospital, Taiwan (2000-2003)
- Postdoctoral Fellow, Division of Oncology (Drs. Ronald & Shoshana Levy Lab), Department of Internal Medicine, Stanford University, USA (1998-2000)
- Graduate Student and Research Assistant, Department of Laboratory Medicine and Pathology (Dr. Daniel Vallera Lab), University of Minnesota, USA (1991-1997)
- Resident, Department of Surgery, Cathy General Hospital at Neihu, Taiwan (1990-1991)
- Resident, Department of Pathology, Taipei Institute of Pathology, Taiwan (1989-1990)

RESEARCH INTERESTS

Dr. Chan's research interests include three directions. The first is being development and conduction of cancer clinical trials. The second is being development and application of trans-differentiation of bone marrow derived mesenchymal stem cells (MSC) into different cell lineages, particular the hepatocyte-like cells. Upon this direction, the mechanism of carcinogenesis of HBV-related hepatocellular carcinoma is also studied. The third is being mechanism study of targeting therapy agents upon different cancers.

RESEARCH ACTIVITIES & ACCOMPLISHMENTS

Dr. Chan is currently involved in several cancer clinical trials including a phase II trial for soft tissue sarcoma and refractory gastrointestinal stromal tumor (GIST) using combination chemotherapy of gemcitabine and docetaxel, an international phase I/II trial for hepatocellular carcinoma using eniluracil and 5-fluorouracil, and initiating the protocol of a phase I clinical trial for refractory cancer using DBPR104, a novel microtubule inhibitor.

The study of trans-differentiation of hepatocyte-like cells from bone-marrow derived mesenchymal stem cells (MSC) has been well established and reproduced in the laboratory. The murine model of liver injury rescued by MSC derived hepatocytes is currently under investigation. In addition, the mechanism of carcinogenesis of hepatocellular carcinoma caused by hepatitis B virus is studied by introducing the HBX protein into differentiating MSC-hepatocyte by lentivirus vector.

As a co-principle of investigator, he also participates in the projects including preclinical study of HCC treatment by targeting EGFR with Cetuximab and Erlotinib, mechanism study and establishment of durg-screening platform for imatinib refractory GIST, and molecular genetic study of mucosa-associated lymphoid tissue (MALT) lymphoma by comparative genomic hybridization (CGH).

HONORS & AWARDS

Fellowship Grant Award, Cure for Lymphoma Foundation, USA: 2-Year Research Grant, 2000-2002 (Declined due to returning to Taiwan)

SELECTED PUBLICATIONS


  1. Chan CH, Liu TW, Chen LT, Chang JY, Whang-Peng J: Long-term complete remission of metastatic gastric cancer after weekly docetaxel, 24 h infusion of high-dose 5-FU/leucovorin and cisplatin. J Gastroenterol Hepatol 20(9):1470-1471, 2005.

  2. Quinn ER, Chan CH, Hadlock KG, Foung SK, Flint M, Levy S: The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 98(13):3745-3749, 2001.

  3. Chan CH, Hadlock KG, Foung SK, Levy S: V(H)1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood 97(4): 1023-1026, 2001.

  4. Chan CH, Blazar BR, Greenfield L, Kreitman RJ, Vallera DA: Reactivity of murine cytokine fusion toxin, diphtheria toxin390-murine interleukin-3 (DT390-mIL-3), with bone marrow progenitor cells. Blood 88(4):1445-1456, 1996.

  5. Chan CH, Blazar BR, Eide CR, Kreitman RJ, Vallera DA: A murine cytokine fusion toxin specifically targeting the murine granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor on normal committed bone marrow progenitor cells and GM-CSF-dependent tumor cells. Blood 86(7):2732-2740, 1995.